Literature DB >> 2787815

Failure of B cells in common variable immunodeficiency to transit from proliferation to differentiation is associated with altered B cell surface-molecule display.

A Saxon1, J V Giorgi, E H Sherr, J M Kagan.   

Abstract

B cells from patients with common variable immunodeficiency (CVI) were investigated as to their surface-molecule display and their functional ability to transit through defined in vitro developmental stages. Patients' B cells were analyzed by dual color-flow cytometry and found to have an abnormal surface-molecule display characterized by depressed Leu 8 and CD21 expression. Membrane immunoglobulin (mu, delta, and light chain) were normally displayed. The lack of Leu 8 and CD21 expression did not represent the normal loss of these antigens from B cells with activation because the cells did not demonstrate enhanced display of activation markers, nor did they demonstrate enhanced display of early B cell molecules, such as common acute lymphocytic leukemia antigen or CD5. Small resting B cells from the patients were isolated and tested for their ability to respond functionally to a series of activation, proliferation, and differentiation signals. B cells from 14 of 17 patients failed to transit from proliferation to differentiation with increased immunoglobulin production when B cells were stimulated with T cell replacing factor +/- phorbol myristate acetate. Cells of one patient failed to proliferate, whereas B cells from the remaining two patients with CVI did not undergo activation (size change and RNA synthesis) when they were exposed to antimu antibody or low-dose phorbol myristate acetate. These studies demonstrate that most patients with CVI have B cells displaying an altered-surface phenotype that is associated with a specific functional defect in transiting from cell proliferation to differentiation and immunoglobulin production.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787815     DOI: 10.1016/0091-6749(89)90177-2

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  12 in total

Review 1.  The second century of the antibody. Molecular perspectives in regulation, pathophysiology, and therapeutic applications.

Authors:  J Braun; A Saxon; R Wall; S L Morrison
Journal:  West J Med       Date:  1992-08

2.  Activated B cells from patients with common variable immunodeficiency proliferate and synthesize immunoglobulin.

Authors:  S Nonoyama; M Farrington; H Ishida; M Howard; H D Ochs
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

3.  Gastric pathology in patients with common variable immunodeficiency.

Authors:  A Zullo; A Romiti; V Rinaldi; A Vecchione; S Tomao; F Aiuti; L Frati; G Luzi
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

4.  Adhesion molecules in common variable immunodeficiency (CVID)--a decrease in L-selectin-positive T lymphocytes.

Authors:  I Nordøy; F Müller; P Aukrust; S S Frøland
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

5.  Intestinal B cell defects in common variable immunodeficiency.

Authors:  E W Herbst; M Armbruster; J A Rump; H P Buscher; H H Peter
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

6.  B cells from a distinct subset of patients with common variable immunodeficiency (CVID) have increased CD95 (Apo-1/fas), diminished CD38 expression, and undergo enhanced apoptosis.

Authors:  A Saxon; B Keld; D Diaz-Sanchez; B C Guo; N Sidell
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

7.  A double-blind, placebo-controlled, crossover therapy study with natural human IL-2 (nhuIL-2) in combination with regular intravenous gammaglobulin (IVIG) infusions in 10 patients with common variable immunodeficiency (CVID).

Authors:  J A Rump; A Jahreis; M Schlesier; S Stecher; H H Peter
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

8.  Immunophenotypical alterations in a subset of patients with common variable immunodeficiency (CVID).

Authors:  E Baumert; G Wolff-Vorbeck; M Schlesier; H H Peter
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

9.  Long-term administration of 13-cis retinoic acid in common variable immunodeficiency: circulating interleukin-6 levels, B-cell surface molecule display, and in vitro and in vivo B-cell antibody production.

Authors:  A Saxon; B Keld; J Braun; A Dotson; N Sidell
Journal:  Immunology       Date:  1993-11       Impact factor: 7.397

10.  Defective CD2 T cell pathway activation in common variable immunodeficiency (CVID).

Authors:  S Zielen; T J Dengler; P Bauscher; S C Meuer
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.